CELLIVERY THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,680 KRW | -29.91% |
|
-.--% | -.--% |
| 2023 | Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index | CI |
| 2021 | Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion. | CI |
| Sales 2022 | 23.16B 16.84M | Sales 2023 | 18.86B 13.71M | Capitalization | 245B 178M |
|---|---|---|---|---|---|
| Net income 2022 | -75.16B -54.64M | Net income 2023 | -32.57B -23.68M | EV / Sales 2022 | 20.8 x |
| Net Debt 2022 | 48.13B 34.99M | Net Debt 2023 | 44.76B 32.54M | EV / Sales 2023 | 15.4 x |
| P/E ratio 2022 |
-4.02
x | P/E ratio 2023 |
-7.51
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.67% |
More Fundamentals
* Assessed data
More news
| 1 day | -29.91% |
3 years
6 680.00
64 050.00
5 years
6 300.00103 425.00
10 years
4 912.50103 425.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dae-Woong Cho
CEO | Chief Executive Officer | 56 | 14-03-13 |
Sun-Hong Kwon
BRD | Director/Board Member | 50 | 21-03-28 |
Byung-Hwa Lee
AUD | Comptroller/Controller/Auditor | 60 | 19-03-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dae-Woong Cho
CEO | Chief Executive Officer | 56 | 14-03-13 |
Sun-Hong Kwon
BRD | Director/Board Member | 50 | 21-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinsonâs disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 179M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- A268600 Stock
